Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer (BBMPI03)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02240537
Recruitment Status : Unknown
Verified April 2016 by Benovus Bio, Inc..
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2014
Last Update Posted : April 19, 2016
Sponsor:
Information provided by (Responsible Party):
Benovus Bio, Inc.

Tracking Information
First Submitted Date  ICMJE September 9, 2014
First Posted Date  ICMJE September 15, 2014
Last Update Posted Date April 19, 2016
Study Start Date  ICMJE January 2015
Estimated Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 25, 2016)
Determine the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and optimal biologic dose (OBD) of BB-MPI-03 and adjuvants in subjects with hematologic cancers who are off treatment and with stable disease (SD) or better. [ Time Frame: 6 months treatment, 6 months follow-up ]
The safety and tolerability of BB-MPI-03 in Montanide emulsion preceded by sargramostim will be measured by:
  • The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), DLTs, and AEs leading to study vaccine discontinuation.
  • The proportion of subjects requiring a modification of the study treatment dose or schedule.
  • Change from baseline in absolute neutrophil counts (ANC) and platelet counts.
  • The proportion of subjects with local injection site reactivity.
  • Proportion of subjects experiencing infections or fevers requiring hospitalization and/or intravenous (IV) antibiotics.
Original Primary Outcome Measures  ICMJE
 (submitted: September 12, 2014)
• Determine the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and optimal biologic dose (OBD) of BB-MPI-03 and adjuvants in subjects with hematologic cancers who are off treatment and with relatively stable disease (SD). [ Time Frame: 6 months treatment, 6 months follow-up ]
The safety and tolerability of BB-MPI-03 in Montanide emulsion preceded by sargramostim will be measured by:
  • The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), DLTs, and AEs leading to study vaccine discontinuation.
  • The proportion of subjects requiring a modification of the study treatment dose or schedule.
  • Change from baseline in absolute neutrophil counts (ANC) and platelet counts.
  • Local injection site reactivity.
  • Proportion of subjects experiencing infections or fevers of unknown origin requiring hospitalization and/or intravenous (IV) antibiotics.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 25, 2016)
  • Determine the in vivo cellular immune response profile of BB-MPI-03 and adjuvants in subjects who receive 5 and 6 intradermal (ID) injections over a 6- month period. [ Time Frame: 12 Months ]
    Immunologic responses (change from Baseline) will be assessed by:
    • DTH reaction to the peptides, as measured and photographed at 7 months using the "ballpoint pen" method.
    • Peptide-specific T-cell proliferation to ELISPOT and tetramer assay.
    • Level of OFA expression on tumor cells at Month 7.
    • Anti-peptide (anti-OFA) antibodies in the serum. These parameters will be measured at D15, D29, M2, M3, M6, M9, and M12 and compared to pre-treatment Baseline. DTH reaction to the peptides and OFA expression will be measured and recorded at 1 month after the last injection (M7).
  • Evaluate any anti-tumor activity of BB-MPI-03 and adjuvants as assessed by disease reduction and lack of disease progression during and after treatment. [ Time Frame: 12 Months ]
    The anti-tumor activity of BB MPI 03 in Montanide emulsion preceded by sargramostim will be measured by: Time to progression (TTP) Overall response rate at Month 7 Best Overall Response
Original Secondary Outcome Measures  ICMJE
 (submitted: September 12, 2014)
  • • • Determine the in vitro and in vivo cellular immune response profile induced by BB-MPI-03 and adjuvants in subjects who receive 6 intradermal (ID) inoculations over a 6- month period. [ Time Frame: 12 Months ]
    Immunologic responses (change from Baseline) will be assessed by:
    • DTH reaction to the peptides, as measured and photographed at 7 months using the "ballpoint pen" method.
    • Peptide-specific T-cell proliferation to peptide pulse and tetramer assay.
    • Autologous tumor cell killing by autologous T-cells in vitro, etc.
    • Level of OFA expression on tumor cells if/when relapsed.
    • Anti-peptide (anti-OFA) antibodies in the serum. These parameters will be measured at D14, D28, M2, M3, M6, M9, and M12 and compared to pre-treatment Baseline. DTH reaction to the peptides and OFA expression will be measured and recorded at 1 month after the last inoculation (M7).
  • • • Evaluate any anti-tumor activity of BB-MPI-03 and adjuvants as assessed by disease recurrence, time to disease recurrence, or disease reduction (complete response [CR]/partial response [PR]/SD) during and after treatment. [ Time Frame: 12 Months ]
    The anti-tumor activity of BB MPI 03 in Montanide emulsion preceded by sargramostim will be measured by:
    • Remission rate in subjects with AML, MDS, and MM with measurable disease.
    • Recurrence rate (disease-free survival) in subjects with AML, MM, and MDS treated after achieving a remission.
    • Time to progression (TTP) of subjects with stable disease.
    • Overall response rate.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
Official Title  ICMJE Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BBMPI03") in Subjects With Hematologic Cancer
Brief Summary The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels. The peptides stimulate cytotoxic T-cells targeting oncofetal antigen (OFA). Subjects with AML, MM, sMM, or MDS who are off treatment and with stable disease or better, or who are not eligible for or refuse allogeneic HSCT are to be enrolled. The study will be conducted at 2 to 4 study centers in the US.
Detailed Description

The current study is a Phase I, open-label, multi-center, dose escalation study designed to evaluate safety, immunogencity, and potential anti-tumor activity of BB-MPI-03 at three peptide plus adjuvant dose levels. Subjects with acute myelogenous leukemia (AML), multiple myeloma (MM), smoldering multiple myeloma (sMM), or myelodysplastic syndrome (MDS) who are off treatment and with stable disease or better or who are not eligible for or refuse allogeneic hematopoietic stem cell transplantation (HSCT) are to be enrolled. The study will be conducted at 2 to 4 study centers in the United States (US).

The study employs a sequential group, open-label, 3+3 dose- escalation design to determine the safety and MTD of BB- MPI-03.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Acute Myelogenous Leukemia (AML)
  • Multiple Myeloma (MM)
  • Myelodysplastic Syndrome (MDS)
  • Smoldering Multiple Myeloma (sMM)
Intervention  ICMJE
  • Drug: Sargramostim
    Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
    Other Name: Leukine
  • Drug: BB-MPI-03
    Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
    Other Name: Multi-peptide Immunotherapy
  • Drug: Montanide

    Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.

    Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration.

    Other Name: Emulsion
Study Arms  ICMJE Experimental: Open Label Treatment Arm
BB-MPI-03 peptides plus montanide plus sargramostim
Interventions:
  • Drug: Sargramostim
  • Drug: BB-MPI-03
  • Drug: Montanide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Actual Enrollment  ICMJE
 (submitted: April 18, 2016)
4
Original Estimated Enrollment  ICMJE
 (submitted: September 12, 2014)
30
Estimated Study Completion Date  ICMJE June 2017
Estimated Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

a. History of morphologically confirmed AML w/ classification other than WHO Acute Promyelocytic Leukemia (FAB M3), based on bone marrow examination.

i. not a candidate for allogeneic HSCT or no intention to move to HSCT at time of enrollment.

ii. Patient's AML could be in morphologic CR or no further cytotoxic chemotherapy is currently being considered.

iii. Completed consolidation chemotherapy, if available and/or appropriate for patient.

iv. Can have history of allogeneic HSCT transplant, but must be off immunosuppression for at least 2 wks. before enrollment and w/o GVHD and/or toxicities from HSCT.

b. Diagnosed in past 5 years w/ smoldering MM at high risk of progressing to symptomatic MM.

i. Diagnosis defined as: Bone marrow infiltration with plasma cells (PCs) ≥10% and presence of a monoclonal component, Ig G ≥3 g/dl or IgA ≥2 g/dl or Bence-Jones proteinuria >1 g/dl and absence of lytic lesions on skeletal survey, absence of hypercalcemia (corrected calcium <11 mg/dl), absence of renal failure (creatinine ≤1.5 x ULN), and absence of anemia (hemoglobin >10 g/dl or not 2 g/dl below LLN).

ii. Must meet one of following:

  • ≥10% PCs in bone marrow and IgG ≥3 g/dl or IgA ≥2 g/dl,
  • ≥10% PCs in bone marrow and serum FLC ratio (involved : uninvolved) >100 in blood, or
  • IgG ≥3 g/dl or IgA ≥2 g/dl and FLC ratio (involved: uninvolved) >100 in blood. c. MM post-treatment disease that is clinically stable and does not require treatment at least 4 weeks prior to enrollment.

    i. At least one line of treatment and achieved at least PR by IMWG ii. Stable disease or better per IMWG based on 2 subsequent assessments at least one month apart d. history of morphologically confirmed MDS i. previously received at least one treatment for MDS, including but not limited to chemotherapy or hypomethylating agent(s). Subjects may be previously untreated if they refuse treatment with or are not appropriate candidates for chemotherapy or hypomethylating agent(s) in the investigator's opinion.

ii. intermediate, high, or very high risk MDS by IPSS-r iii. No curative intent option of allogeneic HSCT or refused consideration for allogeneic HSCT iv. Could have history of allogeneic HSCT transplant and relapsed, but must be off immunosuppression for at least 2 weeks before enrollment and without GVHD and/or toxicities from HSCT.

2. Low, moderate, to high levels of OFA expression by IHC analysis of tumor specimens.

3. HLA-A*02 haplotype.

4. ECOG performance status 0 to 2.

5. 18 years or older.

6. life expectancy ≥3 months.

7. Has following laboratory parameters w/in 28 days:

  • ANC ≥500/mm3
  • ALC >500/mm3
  • PLT ≥25,000/mm3 and may be transfused
  • Hgb >8 g/dL (may have been transfused)
  • Serum creatinine ≤1.5 x ULN
  • Total bilirubin ≤2.0 mg/dL, unless elevated bilirubin due to Gilbert's syndrome
  • ALT and AST less than 5×ULN

    8. If female of child-bearing potential, negative serum pregnancy test result w/in 28 of D1 and agree to abstain from heterosexual intercourse or use acceptable method of birth control (hormonal or barrier method) from Screening through 30 days after last dose

    9. If male having sexual contact with a female of child-bearing potential, agrees to use a latex condom dor agrees to ensure partner uses an acceptable method of birth control (hormonal or barrier method)from Screening through 30 days after last dose

    10. Able to provide written informed consent

Exclusion Criteria

  1. Received chemotherapy, biological therapy, or radiation therapy less than one month before D1
  2. No prior history of active CNS involvement
  3. Grade 2 or higher peripheral neuropathy w/in 28 days
  4. Acute promyelocytic leukemia (FAB M3)
  5. Other active systemic malignancy treated w/ cytotoxic chemotherapy in previous 12 mos.
  6. Monoclonal gammopathy of undetermined significance
  7. For smoldering MM, baseline bone lesions or plasmacytomas
  8. For smoldering MM, lytic lesions on skeletal surveys and hypercalcemia (i.e., ≥11 mg/dL)
  9. Known HIV or hepatitis virus infection
  10. Active infection requiring antibiotics
  11. History of prior or active autoimmune disease such as Lupus or rheumatoid arthritis
  12. Significant kidney or liver disease, uncontrolled severe cardiovascular or pulmonary disease, other uncontrolled medical condition that would compromise subject's ability to tolerate study treatment
  13. Received any investigational treatment w/in 30 days
  14. Receiving systemic glucocorticosteroid >10 mg daily. Concurrent use after registration on study should be restricted to equivalent of prednisone 10 mg per day. Prior or concurrent topical or localized glucocorticosteroid therapy to treat non-malignant comorbid disorders is permitted. Subject requiring routine use of steroid inhalers are not eligible.
  15. Major surgery w/in 4 wks.
  16. G-CSF w/in 30 days
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02240537
Other Study ID Numbers  ICMJE BBMPI03-Hem-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Benovus Bio, Inc.
Study Sponsor  ICMJE Benovus Bio, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Benovus Bio, Inc.
Verification Date April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP